Small is big: Pharma’s R&D brain drain continues as GSK’s Chris Carpenter jumps to upstart Rubius
The steady migration of top R&D execs out of Big Pharma and into little biotech is continuing this morning.
After spending the last decade in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
